Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues    
Royalty $ 2,911 $ 0
Service 92,488 0
Product 210,993 90,035
Total Revenues 306,392 90,035
Operating Expenses    
Research and development 14,572,532 13,022,411
General and administrative 10,937,686 11,676,446
Sales and marketing 6,576,246 3,724,257
Total Operating Expenses 32,086,464 28,423,114
Operating Loss (31,780,072) (28,333,079)
Other Income (Expenses)    
Grant income 1,229,425 1,522,533
Loss on disposal of fixed assets 0 (26,166)
Interest income 125,265 2,734
Interest expense (173,087) (155,803)
Total Other Income 1,181,603 1,343,298
Net Loss (30,598,469) (26,989,781)
Net Loss attributable to Non-Controlling Interest 329,676 175,116
Net Loss attributable to VolitionRx Limited Stockholders (30,268,793) (26,814,665)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 78,771 208,304
Net Comprehensive Loss $ (30,519,698) $ (26,781,477)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders $ (0.55) $ (0.51)
Weighted Average Shares Outstanding    
- Basic and Diluted 55,350,401 52,655,885